Literature DB >> 16002527

AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.

Caroline S Kim1, Vasily V Vasko, Yasuhito Kato, Michael Kruhlak, Motoyasu Saji, Sheue-Yann Cheng, Matthew D Ringel.   

Abstract

The phosphatidylinositol 3-kinase/AKT pathway is crucial to many cell functions, and its dysregulation in tumors is a common finding. The molecular basis of follicular thyroid cancer metastasis is not well understood but may also be influenced by AKT activation. We previously created a knockin mutant mouse that expresses a mutant thyroid hormone receptor-beta gene (TRbetaPV mouse) that spontaneously develops thyroid cancer and distant metastasis similar to human follicular thyroid cancer. In this study, we investigated whether our mouse model exhibits similar AKT activation as human follicular thyroid cancer. Western blot analysis on thyroids from both wild-type and TRbeta(PV/PV) mice revealed elevation of activated AKT in TRbeta(PV/PV) mice. Immunohistochemistry and confocal microscopy reveal activated AKT in both the thyroid and metastatic lesions of TRbeta(PV/PV) mice. Whereas all three AKT isoforms were overexpressed in primary tumors from TRbeta(PV/PV) mice in the cytoplasm of thyroid cancer cells, only AKT1 was also found in the nucleus, matching the localization of activated AKT in a pattern similar to human follicular thyroid cancer. In the metastases, all AKT isoforms correlated with phosphorylated AKT nuclear localization. We created primary thyroid cell lines derived from TRbeta(PV/PV) mice and found reduction of phosphorylated AKT levels or AKT downstream targets diminishes cell motility. Activated AKT is common to both human and mouse follicular thyroid cancer and is correlated with increased cell motility in vitro and metastasis in vivo. Thus, TRbeta(PV/PV) mice could be used to further dissect the detailed pathways underlying the progression and metastasis of follicular thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002527     DOI: 10.1210/en.2005-0172

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  53 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Authors:  Won Gu Kim; Celine J Guigon; Laura Fozzatti; Jeong Won Park; Changxue Lu; Mark C Willingham; Sheue-yann Cheng
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 3.  Pax-8-PPAR-γ fusion protein in thyroid carcinoma.

Authors:  Priyadarshini Raman; Ronald J Koenig
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

4.  Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

Authors:  Celine J Guigon; Laura Fozzatti; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

5.  Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta.

Authors:  Karim Nadra; Silvia I Anghel; Elisabeth Joye; Nguan Soon Tan; Sharmila Basu-Modak; Didier Trono; Walter Wahli; Béatrice Desvergne
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

6.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 7.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

8.  PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Authors:  C J Guigon; L Zhao; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2008-11-10       Impact factor: 9.867

Review 9.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 10.  The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Authors:  Norman L Eberhardt; Stefan K G Grebe; Bryan McIver; Honey V Reddi
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.